Dr Douglas Williams: new drugs and AI will fuel biotech boom
Dr Douglas Williams is a veteran senior executive and board member for several biotech companies. During his time at Biogen, ZymoGenetics, Amgen Immunex and Seattle Genetics, he was involved in the development of several multibillion-dollar treatments, including Enbrel, Tecfidera and Spinraza. Matthew Partridge: The time and cost of clinical trials has been seen as one…